List of Pataday Once Daily Relief drug patents

Pataday Once Daily Relief is owned by Alcon Labs Inc.

Pataday Once Daily Relief contains Olopatadine Hydrochloride.

Pataday Once Daily Relief has a total of 2 drug patents out of which 0 drug patents have expired.

Pataday Once Daily Relief was authorised for market use on 30 January, 2015.

Pataday Once Daily Relief is available in solution/drops;ophthalmic dosage forms.

Pataday Once Daily Relief can be used as treatment of ocular itching associated with allergic conjunctivitis.

The generics of Pataday Once Daily Relief are possible to be released after 19 May, 2032.

PATADAY ONCE DAILY RELIEF Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(9 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(9 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's patent expiration?
More Information on Dosage

PATADAY ONCE DAILY RELIEF family patents

6

United States

4

Korea, Republic of

2

China

2

European Union

1

Uruguay

1

Russia

1

Spain

1

Brazil

1

Colombia

1

Mexico

1

Argentina

1

Taiwan, Province of China

1

Hong Kong

1

South Africa

1

Canada

1

Japan

1

Ukraine

1

Chile

1

Australia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic